与口服抗凝药物使用相关的住院表皮术入院的风险
Margaret B Mitchell1,2, Alan D Workman1,2, Richard Lu1
1Harvard Medical School Boston Massachusetts USA.
Laryngoscope investigative otolaryngology
|August 25, 2023
概括
维生素K抑制剂,但不是直接的口服抗凝剂 (DOAC) 或血小板抑制剂,与住院表入院患者的增加有关. 这一发现表明,抗凝固剂类型之间的出血风险存在潜在差异.
科学领域:
- 内部医学 内部医学
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 膜是急诊室访问和住院的常见原因之一.
- 新型口服抗凝剂 (NOACs) 越来越多地用于各种血栓栓塞性疾病.
- 了解与不同抗凝剂类别相关的表症的比较风险对于患者的安全至关重要.
研究的目的:
- 调查不同类型的口服抗凝剂与住院患者内入院风险之间的关联.
- 为了比较服用维生素K抑制剂,直接口服抗凝剂 (DOACs) 和血小板抑制剂的患者之间发生表症的风险.
主要方法:
- 采用了一种病例控制研究设计.
- 成年患者接受了表 (2019-2021) 被确定为病例.
- 选择了一个对照组,年龄,性别,种族和并发症的匹配率为1:1.
主要成果:
- 维生素K抑制剂存在于5.7%的表病例,而对照组为0.6% (OR 9.48,p=0.02).
- 直接口服抗凝剂 (DOAC) 在4.4%的病例和5.1%的对照中使用 (p=1.0).
- 血小板抑制剂在2.5%的病例和3.8%的对照组中使用 (p=0.75).
结论:
- 与DOACs和血小板抑制剂相比,维生素K抑制剂显示出与住院表症入院的可能性更高的统计学意义上的关联.
- 这些发现表明,抗凝剂的选择可能会影响需要住院治疗的严重表风险.
相关概念视频
Epistaxis
188
Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
188
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
Anticoagulant Drugs: Low-Molecular-Weight Heparins
751
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
751
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
562
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
562


